[go: up one dir, main page]

WO2005041920A3 - Pharmaceutical licofelone formulation - Google Patents

Pharmaceutical licofelone formulation Download PDF

Info

Publication number
WO2005041920A3
WO2005041920A3 PCT/EP2004/012266 EP2004012266W WO2005041920A3 WO 2005041920 A3 WO2005041920 A3 WO 2005041920A3 EP 2004012266 W EP2004012266 W EP 2004012266W WO 2005041920 A3 WO2005041920 A3 WO 2005041920A3
Authority
WO
WIPO (PCT)
Prior art keywords
licofelone
formulation
water soluble
copolymers
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/012266
Other languages
German (de)
French (fr)
Other versions
WO2005041920A2 (en
Inventor
Frank Sievert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merckle GmbH
Original Assignee
Merckle GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merckle GmbH filed Critical Merckle GmbH
Publication of WO2005041920A2 publication Critical patent/WO2005041920A2/en
Publication of WO2005041920A3 publication Critical patent/WO2005041920A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to a solid pharmaceutical formulation containing licofelone or a physiologically acceptable salt thereof and at least one water soluble polymer selected from the group containing hydroxyalkyle celluloses, methyl cellulose, polyvinyl pyrrolidones and copolymers thereof, polyvinyl alcohols, saponified or partially saponified copolymers of N-vinyl pyrrolidone and vinyl esters, and/or at least one water soluble polyol selected from polyethylene glycols having a molecular weight in the region of 8.000 - 20.000 and sugar alcohols. The invention also relates to a formulation which releases the active ingredient in a rapid manner.
PCT/EP2004/012266 2003-10-31 2004-10-29 Pharmaceutical licofelone formulation Ceased WO2005041920A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10351035A DE10351035A1 (en) 2003-10-31 2003-10-31 Pharmaceutical Licofelone formulation
DE10351035.4 2003-10-31

Publications (2)

Publication Number Publication Date
WO2005041920A2 WO2005041920A2 (en) 2005-05-12
WO2005041920A3 true WO2005041920A3 (en) 2005-07-14

Family

ID=34485181

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/012266 Ceased WO2005041920A2 (en) 2003-10-31 2004-10-29 Pharmaceutical licofelone formulation

Country Status (4)

Country Link
AR (1) AR046205A1 (en)
DE (1) DE10351035A1 (en)
TW (1) TW200524592A (en)
WO (1) WO2005041920A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109718220A (en) * 2017-10-27 2019-05-07 天津药物研究院有限公司 The preparation method of ML-4000 clathrate capsule
EP3593792A1 (en) 2018-07-11 2020-01-15 Welding GmbH & Co. KG Pharmaceutical composition comprising 6- (4-chlorophenyl) -2,2-dimethyl-7-phenyl-2,3-dihydro-1h-pyrrolizine-5-yl acetic acid cholin salt
WO2023089636A1 (en) * 2021-11-21 2023-05-25 Aizant Drug Research Solutions Private Limited Pharmaceutical compositions of licofelone

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996041626A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US20020143033A1 (en) * 1996-02-13 2002-10-03 G.D. Searle & Co. Immunosuppresive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
WO2002089791A2 (en) * 2001-04-30 2002-11-14 Zouboulis Christos C Acne treatment with lipooxigenase inhibitors
WO2003097041A1 (en) * 2002-05-17 2003-11-27 Merckle Gmbh Annelated pyrrole compounds as proton pump inhibitors for treating ulcer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996041626A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US6136839A (en) * 1995-06-12 2000-10-24 G. D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US20020143033A1 (en) * 1996-02-13 2002-10-03 G.D. Searle & Co. Immunosuppresive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
WO2002089791A2 (en) * 2001-04-30 2002-11-14 Zouboulis Christos C Acne treatment with lipooxigenase inhibitors
WO2003097041A1 (en) * 2002-05-17 2003-11-27 Merckle Gmbh Annelated pyrrole compounds as proton pump inhibitors for treating ulcer

Also Published As

Publication number Publication date
TW200524592A (en) 2005-08-01
AR046205A1 (en) 2005-11-30
WO2005041920A2 (en) 2005-05-12
DE10351035A1 (en) 2005-05-25

Similar Documents

Publication Publication Date Title
WO2002051385A8 (en) Solid dispersions of nitrate active principles
DK1796484T3 (en) confectionery product
CA2371940A1 (en) Pregelatinized starch in a controlled release formulation
CA2331264A1 (en) Compositions and methods for drug delivery
WO2000041681A3 (en) MEDICINAL FORMULATIONS CONTAINING AN OPIOID AND AN α-ANTAGONIST
MXPA03008886A (en) Polyhydroxyalkanoate copolymer and polylactic acid polymer compositions for laminates and films.
CA2411277A1 (en) Neurotoxin implant
WO2004010998A8 (en) Sustained-release tablet comprising reboxetine
CA2311438A1 (en) Self-tanning mousse
MA30064B1 (en) PROLONGED RELEASE FORMULATION COMPRISING OCTREOTIDE AND TWO COPOLYMERS OF POLYLACTIDE-GLYCOLIDE OR MORE
WO2001060335A3 (en) Delivery systems using preformed biodegradable polymer compositions and methods
WO2000040203A3 (en) Polymeric delivery agents and delivery agent compounds
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
WO1998009597A3 (en) Cushioning beads and tablet comprising the same capable of forming a suspension
WO2006059029A3 (en) Solutions viscoelastiques renfermant du hyaluronate de sodium et de l ' hydroxypropylmethylcellulose
WO2002048141A1 (en) Medicinal compositions improved in solublity in water
WO2008148742A3 (en) Pharmaceutical formulation for the production of rapidly disintegrating tablets
JP2008539802A5 (en)
WO2007068615A3 (en) Hcv prodrug formulation
CA2346868A1 (en) Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
MY130332A (en) Pharmaceutical formulation comprising iota-carrageenan and at least one neutral gelling polymer
UA94917C2 (en) Topical formulations
WO2003059382A3 (en) Pharmaceutical compositions comprising polyanionic polymers and amphiphilic block copolymers and methods of use thereof to improve gene expression
AU2697100A (en) Pharmaceutical capsule compositions containing loratadine and pseudoephedrine
WO2004100883A3 (en) Method for preparing thermoformed compositions containing acrylic polymer binders, pharmaceutual dosage forms and methods of preparing the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase